{"gene":"TG_253330","gene_symbol":"BPK1","run_date":"2026-09-08T12:58:25","timeline":{"discoveries":[{"year":2013,"finding":"BPK1 is a cyst wall component that co-immunoprecipitates with at least four proteins: MAG1, MCP4, GRA8, and GRA9, from in vitro bradyzoite cultures.","method":"Immunoprecipitation from in vitro bradyzoite cultures followed by protein identification","journal":"Eukaryotic cell","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — single Co-IP experiment identifying binding partners, single lab","pmids":["23291621"],"is_preprint":false,"attribution":[{"species":"Toxoplasma gondii","strain":""}]},{"year":2013,"finding":"Deletion of BPK1 (Δbpk1) results in significantly smaller cysts at 8 weeks post-infection compared to parental and complemented strains, but no defect in in vitro cyst formation or cyst burden at 4 weeks post-intraperitoneal infection.","method":"Gene knockout (Δbpk1), in vitro and in vivo cyst formation assays, comparison with complemented strain","journal":"Eukaryotic cell","confidence":"High","confidence_rationale":"Tier 2 / Moderate — clean KO with specific phenotypic readout, complementation control, single lab with multiple assays","pmids":["23291621"],"is_preprint":false,"attribution":[{"species":"Toxoplasma gondii","strain":""}]},{"year":2013,"finding":"BPK1 knockout cysts are significantly more sensitive to pepsin-acid treatment than parental or complemented strains, indicating BPK1 contributes to cyst wall integrity.","method":"Pepsin-acid treatment of in vivo cysts from Δbpk1, parental, and complemented strains","journal":"Eukaryotic cell","confidence":"High","confidence_rationale":"Tier 2 / Moderate — clean KO with specific biochemical phenotype, complementation control restoring resistance","pmids":["23291621"],"is_preprint":false,"attribution":[{"species":"Toxoplasma gondii","strain":""}]},{"year":2013,"finding":"Δbpk1 cysts show significantly reduced ability to establish oral infection compared to parental and complemented strains, demonstrating BPK1 is required for efficient oral transmission.","method":"Oral infection assay with Δbpk1 cysts in animal model, comparison with parental and BPK1-complemented strains","journal":"Eukaryotic cell","confidence":"High","confidence_rationale":"Tier 2 / Moderate — clean KO with defined in vivo phenotype, complementation control, single lab","pmids":["23291621"],"is_preprint":false,"attribution":[{"species":"Toxoplasma gondii","strain":""}]},{"year":2013,"finding":"Structural and evolutionary analysis classifies BPK1 as a pseudokinase belonging to a basal ROPK clade (termed ROPKL), sharing ROPK-specific conservation patterns including a hinge-region insert and a disulfide bridge in the substrate-binding lobe, but lacking features of active kinases.","method":"Comparative sequence and structural analysis of ROPK family members across Toxoplasma gondii, Neospora caninum, and Eimeria tenella genomes","journal":"BMC evolutionary biology","confidence":"Low","confidence_rationale":"Tier 4 / Moderate — computational/comparative structural analysis only, no direct biochemical validation of BPK1 pseudokinase activity","pmids":["23742205"],"is_preprint":false,"attribution":[{"species":"Toxoplasma gondii","strain":""}]},{"year":2018,"finding":"BPK1 expression in tachyzoites is suppressed by the ApiAP2 transcriptional repressor AP2IV-4; deletion of AP2IV-4 results in ectopic expression of BPK1 in replicating tachyzoites, establishing BPK1 as a transcriptional target of AP2IV-4.","method":"AP2IV-4 locus deletion with immunofluorescence/Western detection of BPK1 expression in tachyzoites","journal":"PLoS pathogens","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis via transcription factor KO with defined molecular readout, single lab","pmids":["29718996"],"is_preprint":false,"attribution":[{"species":"Toxoplasma gondii","strain":""}]},{"year":2019,"finding":"BPK1 was identified as a component of the purified cyst wall fraction by LC-MS/MS proteomics of CST1-immunoprecipitated cyst wall fragments, confirming its localization to the cyst wall.","method":"Cyst wall enrichment by Percoll gradient, CST1 antibody immunoprecipitation, and LC-MS/MS mass spectrometry","journal":"mBio","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — proteomic identification corroborating prior localization data, replicated by independent lab","pmids":["31040239"],"is_preprint":false,"attribution":[{"species":"Toxoplasma gondii","strain":""}]}],"current_model":"BPK1 is a bradyzoite-specific pseudokinase component of the Toxoplasma gondii cyst wall that associates with MAG1, MCP4, GRA8, and GRA9; it is transcriptionally repressed in tachyzoites by the ApiAP2 factor AP2IV-4, and is required for cyst wall integrity (resistance to pepsin-acid treatment), normal cyst size development, and efficient oral transmission, though it is dispensable for in vitro cyst formation and initial intraperitoneal infection."},"narrative":{"mechanistic_narrative":"BPK1 (bradyzoite pseudokinase 1) is a bradyzoite-specific component of the Toxoplasma gondii cyst wall that contributes to cyst wall integrity and oral transmissibility of the parasite [PMID:23291621]. It resides in the cyst wall, where it co-immunoprecipitates with the wall proteins MAG1, MCP4, GRA8, and GRA9 [PMID:23291621] and is recovered in purified CST1-associated cyst wall fractions [PMID:31040239]. Its stage-specific restriction to bradyzoites is enforced transcriptionally: the ApiAP2 factor AP2IV-4 represses BPK1 in replicating tachyzoites, and loss of AP2IV-4 drives ectopic BPK1 expression in tachyzoites [PMID:29718996]. Functionally, deletion of BPK1 yields smaller cysts, cysts that are hypersensitive to pepsin-acid treatment, and a defect in establishing oral infection, while leaving in vitro cyst formation and initial intraperitoneal cyst burden intact [PMID:23291621]. Comparative structural analysis places BPK1 in a basal ROP-kinase clade as a pseudokinase lacking the hallmarks of catalytic activity [PMID:23742205], so it likely acts as a structural or scaffolding element of the wall rather than a signaling enzyme; no direct biochemical activity or substrate has been characterized in the available corpus.","teleology":[{"year":2013,"claim":"Establishing that BPK1 is a physical constituent of the cyst wall and defines its molecular neighborhood answered where and with what BPK1 acts.","evidence":"Co-immunoprecipitation from in vitro bradyzoite cultures identifying MAG1, MCP4, GRA8, and GRA9 as partners","pmids":["23291621"],"confidence":"Medium","gaps":["Single Co-IP without reciprocal validation","Does not establish direct versus indirect associations","Stoichiometry and architecture of the complex unknown"],"attribution":[{"species":"Toxoplasma gondii","strain":""}]},{"year":2013,"claim":"Gene knockout with complementation tested whether BPK1 is functionally required, showing it is dispensable for cyst formation but needed for normal cyst size, wall integrity, and oral transmission.","evidence":"Δbpk1 knockout with complemented control assayed for in vitro/in vivo cyst formation, pepsin-acid resistance, and oral infection","pmids":["23291621"],"confidence":"High","gaps":["Molecular basis of the wall-integrity defect unresolved","Whether smaller cyst size and transmission defect share a common mechanism unknown","No biochemical activity linked to the phenotype"],"attribution":[{"species":"Toxoplasma gondii","strain":""}]},{"year":2013,"claim":"Comparative structural analysis addressed whether BPK1 is catalytically active, classifying it as a pseudokinase in a basal ROPK clade.","evidence":"Comparative sequence/structural analysis of ROPK family across T. gondii, N. caninum, and E. tenella","pmids":["23742205"],"confidence":"Low","gaps":["Computational only; pseudokinase status not confirmed biochemically","No test of residual catalytic or nucleotide-binding activity","Scaffolding function inferred, not demonstrated"],"attribution":[{"species":"Toxoplasma gondii","strain":""}]},{"year":2018,"claim":"Deleting the transcription factor AP2IV-4 answered how BPK1 stage-specificity is controlled, identifying it as an AP2IV-4-repressed target derepressed in tachyzoites.","evidence":"AP2IV-4 locus deletion with immunofluorescence/Western detection of BPK1 in tachyzoites","pmids":["29718996"],"confidence":"Medium","gaps":["Does not establish direct promoter binding by AP2IV-4","Functional consequence of ectopic tachyzoite expression not assessed"],"attribution":[{"species":"Toxoplasma gondii","strain":""}]},{"year":2019,"claim":"Independent proteomics of purified cyst wall confirmed BPK1 localization, corroborating the original Co-IP-based assignment.","evidence":"Percoll-enriched, CST1-immunoprecipitated cyst wall analyzed by LC-MS/MS","pmids":["31040239"],"confidence":"Medium","gaps":["Proteomic detection does not resolve submolecular position within the wall","Does not distinguish structural from regulatory role"],"attribution":[{"species":"Toxoplasma gondii","strain":""}]},{"year":null,"claim":"Whether BPK1 has any residual biochemical activity or a defined mechanistic role in wall assembly beyond being a structural/scaffolding component remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No direct biochemical assay of pseudokinase activity","Mechanism linking BPK1 loss to reduced wall integrity and transmission unknown","Direct versus indirect nature of partner interactions not established"],"attribution":[{"species":"Toxoplasma gondii","strain":""}]}],"mechanism_profile":{"molecular_activity":[],"localization":[],"pathway":[],"complexes":["Cyst wall protein assembly with MAG1, MCP4, GRA8, GRA9"],"partners":["MAG1","MCP4","GRA8","GRA9","AP2IV-4 (TRANSCRIPTIONAL REPRESSOR)"],"other_free_text":["Bradyzoite-specific pseudokinase of the basal ROPKL clade; catalytically inactive by structural prediction [#4]","Required for cyst wall integrity (pepsin-acid resistance), normal cyst size, and efficient oral transmission; dispensable for in vitro cyst formation and initial intraperitoneal cyst burden [#1, #2, #3]","Transcriptionally repressed in tachyzoites by ApiAP2 factor AP2IV-4 [#5]"]},"strain_conflicts":[]},"prefetch_data":{},"corpus_meta":[{"pmid":"29718996","id":"PMC_29718996","title":"Transcriptional repression by ApiAP2 factors is central to chronic toxoplasmosis.","date":"2018","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/29718996","citation_count":77,"is_preprint":false},{"pmid":"23742205","id":"PMC_23742205","title":"Structural and evolutionary adaptation of rhoptry kinases and pseudokinases, a family of coccidian virulence factors.","date":"2013","source":"BMC evolutionary biology","url":"https://pubmed.ncbi.nlm.nih.gov/23742205","citation_count":69,"is_preprint":false},{"pmid":"31040239","id":"PMC_31040239","title":"Enrichment and Proteomic Characterization of the Cyst Wall from In Vitro Toxoplasma gondii Cysts.","date":"2019","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/31040239","citation_count":65,"is_preprint":false},{"pmid":"23291621","id":"PMC_23291621","title":"Bradyzoite pseudokinase 1 is crucial for efficient oral infectivity of the Toxoplasma gondii tissue cyst.","date":"2013","source":"Eukaryotic cell","url":"https://pubmed.ncbi.nlm.nih.gov/23291621","citation_count":41,"is_preprint":false},{"pmid":"40244171","id":"PMC_40244171","title":"Role of Toxoplasma gondii p24δ in Regulating the Transition from Tachyzoite to Bradyzoite Development.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40244171","citation_count":1,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":5081,"output_tokens":1688,"usd":0.020282,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":6882,"output_tokens":2483,"usd":0.048243,"stage2_stop_reason":"end_turn"},"total_usd":0.068525,"stage1_batch_id":"msgbatch_01TEPNZ4MCzJ7xtsNwosiDRk","stage2_batch_id":"msgbatch_01FQShM7n1sfCr4pWTDShmki","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2013,\n      \"finding\": \"BPK1 is a cyst wall component that co-immunoprecipitates with at least four proteins: MAG1, MCP4, GRA8, and GRA9, from in vitro bradyzoite cultures.\",\n      \"method\": \"Immunoprecipitation from in vitro bradyzoite cultures followed by protein identification\",\n      \"journal\": \"Eukaryotic cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — single Co-IP experiment identifying binding partners, single lab\",\n      \"pmids\": [\"23291621\"],\n      \"is_preprint\": false,\n      \"attribution\": [{\"species\": \"Toxoplasma gondii\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Deletion of BPK1 (Δbpk1) results in significantly smaller cysts at 8 weeks post-infection compared to parental and complemented strains, but no defect in in vitro cyst formation or cyst burden at 4 weeks post-intraperitoneal infection.\",\n      \"method\": \"Gene knockout (Δbpk1), in vitro and in vivo cyst formation assays, comparison with complemented strain\",\n      \"journal\": \"Eukaryotic cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KO with specific phenotypic readout, complementation control, single lab with multiple assays\",\n      \"pmids\": [\"23291621\"],\n      \"is_preprint\": false,\n      \"attribution\": [{\"species\": \"Toxoplasma gondii\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"BPK1 knockout cysts are significantly more sensitive to pepsin-acid treatment than parental or complemented strains, indicating BPK1 contributes to cyst wall integrity.\",\n      \"method\": \"Pepsin-acid treatment of in vivo cysts from Δbpk1, parental, and complemented strains\",\n      \"journal\": \"Eukaryotic cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KO with specific biochemical phenotype, complementation control restoring resistance\",\n      \"pmids\": [\"23291621\"],\n      \"is_preprint\": false,\n      \"attribution\": [{\"species\": \"Toxoplasma gondii\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Δbpk1 cysts show significantly reduced ability to establish oral infection compared to parental and complemented strains, demonstrating BPK1 is required for efficient oral transmission.\",\n      \"method\": \"Oral infection assay with Δbpk1 cysts in animal model, comparison with parental and BPK1-complemented strains\",\n      \"journal\": \"Eukaryotic cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KO with defined in vivo phenotype, complementation control, single lab\",\n      \"pmids\": [\"23291621\"],\n      \"is_preprint\": false,\n      \"attribution\": [{\"species\": \"Toxoplasma gondii\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Structural and evolutionary analysis classifies BPK1 as a pseudokinase belonging to a basal ROPK clade (termed ROPKL), sharing ROPK-specific conservation patterns including a hinge-region insert and a disulfide bridge in the substrate-binding lobe, but lacking features of active kinases.\",\n      \"method\": \"Comparative sequence and structural analysis of ROPK family members across Toxoplasma gondii, Neospora caninum, and Eimeria tenella genomes\",\n      \"journal\": \"BMC evolutionary biology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Moderate — computational/comparative structural analysis only, no direct biochemical validation of BPK1 pseudokinase activity\",\n      \"pmids\": [\"23742205\"],\n      \"is_preprint\": false,\n      \"attribution\": [{\"species\": \"Toxoplasma gondii\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"BPK1 expression in tachyzoites is suppressed by the ApiAP2 transcriptional repressor AP2IV-4; deletion of AP2IV-4 results in ectopic expression of BPK1 in replicating tachyzoites, establishing BPK1 as a transcriptional target of AP2IV-4.\",\n      \"method\": \"AP2IV-4 locus deletion with immunofluorescence/Western detection of BPK1 expression in tachyzoites\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis via transcription factor KO with defined molecular readout, single lab\",\n      \"pmids\": [\"29718996\"],\n      \"is_preprint\": false,\n      \"attribution\": [{\"species\": \"Toxoplasma gondii\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BPK1 was identified as a component of the purified cyst wall fraction by LC-MS/MS proteomics of CST1-immunoprecipitated cyst wall fragments, confirming its localization to the cyst wall.\",\n      \"method\": \"Cyst wall enrichment by Percoll gradient, CST1 antibody immunoprecipitation, and LC-MS/MS mass spectrometry\",\n      \"journal\": \"mBio\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — proteomic identification corroborating prior localization data, replicated by independent lab\",\n      \"pmids\": [\"31040239\"],\n      \"is_preprint\": false,\n      \"attribution\": [{\"species\": \"Toxoplasma gondii\", \"strain\": \"\"}]\n    }\n  ],\n  \"current_model\": \"BPK1 is a bradyzoite-specific pseudokinase component of the Toxoplasma gondii cyst wall that associates with MAG1, MCP4, GRA8, and GRA9; it is transcriptionally repressed in tachyzoites by the ApiAP2 factor AP2IV-4, and is required for cyst wall integrity (resistance to pepsin-acid treatment), normal cyst size development, and efficient oral transmission, though it is dispensable for in vitro cyst formation and initial intraperitoneal infection.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"BPK1 (bradyzoite pseudokinase 1) is a bradyzoite-specific component of the Toxoplasma gondii cyst wall that contributes to cyst wall integrity and oral transmissibility of the parasite [#0, #2, #3]. It resides in the cyst wall, where it co-immunoprecipitates with the wall proteins MAG1, MCP4, GRA8, and GRA9 [#0] and is recovered in purified CST1-associated cyst wall fractions [#6]. Its stage-specific restriction to bradyzoites is enforced transcriptionally: the ApiAP2 factor AP2IV-4 represses BPK1 in replicating tachyzoites, and loss of AP2IV-4 drives ectopic BPK1 expression in tachyzoites [#5]. Functionally, deletion of BPK1 yields smaller cysts, cysts that are hypersensitive to pepsin-acid treatment, and a defect in establishing oral infection, while leaving in vitro cyst formation and initial intraperitoneal cyst burden intact [#1, #2, #3]. Comparative structural analysis places BPK1 in a basal ROP-kinase clade as a pseudokinase lacking the hallmarks of catalytic activity [#4], so it likely acts as a structural or scaffolding element of the wall rather than a signaling enzyme; no direct biochemical activity or substrate has been characterized in the available corpus.\",\n  \"teleology\": [\n    {\n      \"year\": 2013,\n      \"claim\": \"Establishing that BPK1 is a physical constituent of the cyst wall and defines its molecular neighborhood answered where and with what BPK1 acts.\",\n      \"evidence\": \"Co-immunoprecipitation from in vitro bradyzoite cultures identifying MAG1, MCP4, GRA8, and GRA9 as partners\",\n      \"pmids\": [\"23291621\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single Co-IP without reciprocal validation\", \"Does not establish direct versus indirect associations\", \"Stoichiometry and architecture of the complex unknown\"],\n      \"attribution\": [{\"species\": \"Toxoplasma gondii\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Gene knockout with complementation tested whether BPK1 is functionally required, showing it is dispensable for cyst formation but needed for normal cyst size, wall integrity, and oral transmission.\",\n      \"evidence\": \"Δbpk1 knockout with complemented control assayed for in vitro/in vivo cyst formation, pepsin-acid resistance, and oral infection\",\n      \"pmids\": [\"23291621\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of the wall-integrity defect unresolved\", \"Whether smaller cyst size and transmission defect share a common mechanism unknown\", \"No biochemical activity linked to the phenotype\"],\n      \"attribution\": [{\"species\": \"Toxoplasma gondii\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Comparative structural analysis addressed whether BPK1 is catalytically active, classifying it as a pseudokinase in a basal ROPK clade.\",\n      \"evidence\": \"Comparative sequence/structural analysis of ROPK family across T. gondii, N. caninum, and E. tenella\",\n      \"pmids\": [\"23742205\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Computational only; pseudokinase status not confirmed biochemically\", \"No test of residual catalytic or nucleotide-binding activity\", \"Scaffolding function inferred, not demonstrated\"],\n      \"attribution\": [{\"species\": \"Toxoplasma gondii\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Deleting the transcription factor AP2IV-4 answered how BPK1 stage-specificity is controlled, identifying it as an AP2IV-4-repressed target derepressed in tachyzoites.\",\n      \"evidence\": \"AP2IV-4 locus deletion with immunofluorescence/Western detection of BPK1 in tachyzoites\",\n      \"pmids\": [\"29718996\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not establish direct promoter binding by AP2IV-4\", \"Functional consequence of ectopic tachyzoite expression not assessed\"],\n      \"attribution\": [{\"species\": \"Toxoplasma gondii\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Independent proteomics of purified cyst wall confirmed BPK1 localization, corroborating the original Co-IP-based assignment.\",\n      \"evidence\": \"Percoll-enriched, CST1-immunoprecipitated cyst wall analyzed by LC-MS/MS\",\n      \"pmids\": [\"31040239\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Proteomic detection does not resolve submolecular position within the wall\", \"Does not distinguish structural from regulatory role\"],\n      \"attribution\": [{\"species\": \"Toxoplasma gondii\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Whether BPK1 has any residual biochemical activity or a defined mechanistic role in wall assembly beyond being a structural/scaffolding component remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No direct biochemical assay of pseudokinase activity\", \"Mechanism linking BPK1 loss to reduced wall integrity and transmission unknown\", \"Direct versus indirect nature of partner interactions not established\"],\n      \"attribution\": [{\"species\": \"Toxoplasma gondii\", \"strain\": \"\"}]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016301\", \"supporting_discovery_ids\": [4], \"attribution\": [{\"species\": \"Toxoplasma gondii\", \"strain\": \"\"}]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0106306\", \"supporting_discovery_ids\": [0, 6], \"attribution\": [{\"species\": \"Toxoplasma gondii\", \"strain\": \"\"}]}\n    ],\n    \"pathway\": [],\n    \"complexes\": [\n      \"Cyst wall protein assembly with MAG1, MCP4, GRA8, GRA9\"\n    ],\n    \"partners\": [\n      \"MAG1\",\n      \"MCP4\",\n      \"GRA8\",\n      \"GRA9\",\n      \"AP2IV-4 (transcriptional repressor)\"\n    ],\n    \"other_free_text\": [\n      \"Bradyzoite-specific pseudokinase of the basal ROPKL clade; catalytically inactive by structural prediction [#4]\",\n      \"Required for cyst wall integrity (pepsin-acid resistance), normal cyst size, and efficient oral transmission; dispensable for in vitro cyst formation and initial intraperitoneal cyst burden [#1, #2, #3]\",\n      \"Transcriptionally repressed in tachyzoites by ApiAP2 factor AP2IV-4 [#5]\"\n    ]\n  },\n  \"strain_conflicts\": []\n}\n```","audit_flag":null,"strains":[{"strain":"ME49","gene_id":"TGME49_253330","name":"BPK1","product":"bradyzoite pseudokinase BPK1","uniprot_acc":"S8FDR4","chromosome":"TGME49_chrIII","start_pos":857863},{"strain":"GT1","gene_id":"TGGT1_253330","name":null,"product":"Rhoptry kinase family protein","uniprot_acc":null,"chromosome":"TGGT1_chrIII","start_pos":839240},{"strain":"RH88","gene_id":"TGRH88_004990","name":null,"product":"Rhoptry kinase family protein","uniprot_acc":null,"chromosome":"CM023084","start_pos":1746914},{"strain":"VEG","gene_id":"TGVEG_253330","name":null,"product":"Rhoptry kinase family protein","uniprot_acc":"B9QIV8","chromosome":"TGVEG_chrIII","start_pos":866649}]}